Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMA-341 in Advanced or Metastatic Solid Tumors
NCT06974110Phase 1Recruiting
- Sponsor
- MOMA Therapeutics
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of MOMA-341 in solid tumor (3 arms), sponsored by MOMA Therapeutics. Primary endpoint: Adverse Events up to 35 months. Started Jul 2025; status: recruiting.
02
Drugs
MOMA-341
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06974110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974110.